On July 6, Duality Biotherapeutics-B rose 9.01% in regular trading, trading at HK$232.0/share, with turnover of HK$105 million. The rally was driven by the company's STAR Market IPO review status being upgraded to \"inquired,\" marking further progress in its listing process, combined with continued catalysts in the ADC sector.

According to the Shanghai Stock Exchange website, Duality Biotherapeutics' STAR Market IPO application, which was accepted on June 12, has now advanced to the inquiry stage. The company plans to raise approximately RMB 4.1 billion for new drug R&D. Meanwhile, recent industry research reports indicate the global ADC market is projected to exceed $100 billion by 2032, with Chinese companies demonstrating increasingly significant competitive advantages.

Within the Biotechnology sector, peers traded higher with REMEGEN up 3.82%, INNOVENT BIO up 3.3%, SKB BIO up 1.7%, 3SBIO up 1.69%, and AKESO up 0.59%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)